Vitamin D and Autoimmune Diseases

  • Shir Azrielant
  • Yehuda ShoenfeldEmail author
Part of the Contemporary Endocrinology book series (COE)


Vitamin D has a crucial role in preserving musculoskeletal health and modulating the immune system; the latter has been a subject of great interest in recent years. Vitamin D deficiency is common in the general population and even more so among patients with various autoimmune diseases. Vitamin D deficiency has been previously linked to various autoimmune diseases, including multiple sclerosis, type 1 diabetes, inflammatory bowel diseases, and rheumatoid arthritis. In this chapter, the association between vitamin D deficiency and various autoimmune diseases will be discussed, as well as the possible therapeutic implications derived from this relationship.


Vitamin D Autoimmunity SLE Type 1 diabetes MS IBD RA Psoriasis 



Autoimmune hepatitis


Autoimmune thyroid diseases


Body mass index


Crohn’s disease


Diffuse cutaneous systemic sclerosis


Inflammatory bowel diseases


Juvenile-onset systemic lupus erythematosus




Limited cutaneous systemic sclerosis


Magnetic resonance imaging


Multiple sclerosis


Primary biliary cholangitis


Rheumatoid arthritis


Relative risk


Systemic lupus erythematosus


Systemic sclerosis


Transforming growth factor


T helper cells


T regulatory cells


Ulcerative colitis




Ultraviolet B


Vitamin D receptor


  1. 1.
    Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis. 2007;66(9):1137–42.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun Rev. 2007;7(1):59–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80:1678–88.CrossRefGoogle Scholar
  4. 4.
    Mok CC. Vitamin D and systemic lupus erythematosus: an update. Expert Rev Clin Immunol. 2013;9(5):453–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 1983;57(6):1308–10. The Endocrine Society.PubMedCrossRefGoogle Scholar
  6. 6.
    Peelen E, Knippenberg S, Muris A-H, Thewissen M, Smolders J, Tervaert JWC, et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev. 2011;10(12):733–43. Elsevier.PubMedCrossRefGoogle Scholar
  7. 7.
    Schneider L, Dos Santos ASP, Santos M, da Silva Chakr RM, Monticielo OA. Vitamin D and systemic lupus erythematosus: state of the art. Clin Rheumatol. 2014;33(8):1033–8.PubMedGoogle Scholar
  8. 8.
    Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology. 2002;35(1):126–31. Wiley Online Library.PubMedCrossRefGoogle Scholar
  9. 9.
    Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med. 2004;229(11):1136–42. SAGE Publications.CrossRefGoogle Scholar
  10. 10.
    Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol. 2013;45(2):256–66.PubMedCrossRefGoogle Scholar
  11. 11.
    Rosen Y, Daich J, Soliman I, Brathwaite E, Shoenfeld Y. Vitamin D and autoimmunity. Scand J Rheumatol. 2016;18:1–9. Taylor & Francis.Google Scholar
  12. 12.
    Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev. 2010;9:709–15.PubMedCrossRefGoogle Scholar
  14. 14.
    de Souza VA, Bastos MG, Fernandes NMDS, Mansur HN, Raposo NRB, de Souza DMK, et al. Association of hypovitaminosis D with systemic lupus erythematosus and inflammation. J Bras Nefrol. 2014;36(4):430–6.PubMedGoogle Scholar
  15. 15.
    McGhie T, Deceulaer K, Walters C, Soyibo A, Lee M. Vitamin D levels in Jamaican patients with systemic lupus erythematosus. Lupus. 2014;23:1–5.CrossRefGoogle Scholar
  16. 16.
    Yap KS, Morand EF. Vitamin D and systemic lupus erythematosus: continued evolution. Int J Rheum Dis. 2015;18(2):242–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Schoindre Y, Jallouli M, Tanguy M-L, Ghillani P, Galicier L, Aumaitre O, et al. Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Sci Med. 2014;1(1):e000027.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med. 2000;223(3):230–3. Wiley Online Library.PubMedCrossRefGoogle Scholar
  19. 19.
    Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80(6):1678S–88S. Am Soc Nutrition.PubMedCrossRefGoogle Scholar
  20. 20.
    Squance ML, Reeves GEM, Tran HA. Vitamin D levels are associated with expression of SLE, but not flare frequency. Int J Rheumatol. 2014;2014:1–10.CrossRefGoogle Scholar
  21. 21.
    Sabio JM, Vargas-Hitos JA, Martinez-Bordonado J, Navarrete-Navarrete N, Diaz-Chamorro A, Olvera-Porcel C, et al. Association between low 25-hydroxyvitamin D, insulin resistance and arterial stiffness in nondiabetic women with systemic lupus erythematosus. Lupus. 2014;24:155–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007;56(6):2092–4. Wiley Online Library.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Winkelmann RR, Kim GK, Del Rosso JQ. Treatment of cutaneous lupus erythematosus: review and assessment of treatment benefits based on Oxford Centre for Evidence-based Medicine Criteria. J Clin Aesthet Dermatol. 2013;6(1):27–38. Matrix Medical Communications.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Stagi S, Cavalli L, Bertini F, de Martino M, Cerinic MM, Brandi M, et al. Vitamin D levels in children, adolescents, and young adults with juvenile-onset systemic lupus erythematosus: a cross-sectional study. Lupus. 2014;23:1059–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Garf KE, Marzouk H, Farag Y, Rasheed L, Garf AE. Vitamin D status in Egyptian patients with juvenile-onset systemic lupus erythematosus. Rheumatol Int. 2015;35(9):1535–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Chaiamnuay S, Chailurkit L, Narongroeknawin P, Asavatanabodee P, Laohajaroensombat S, Chaiamnuay P. Current daily glucocorticoid use and serum creatinine levels are associated with lower 25(OH) vitamin D levels in Thai patients with systemic lupus erythematosus. J Clin Rheumatol. 2013;19(3):121–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Azrielant S, Shoenfeld Y. Eppur Si Muove: vitamin D is essential in preventing and modulating SLE. Lupus. 2016;25(6):563–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Handono K, Sidarta YO, Pradana BA, Nugroho RA, Hartono IA, Kalim H, et al. Vitamin D prevents endothelial damage induced by increased neutrophil extracellular traps formation in patients with systemic lupus erythematosus. Acta Med Indones - Indones J Intern Med. 2014;46(3):189–98.Google Scholar
  30. 30.
    Wahono CS, Rusmini H, Soelistyoningsih D, Hakim R, Handono K, Endharti AT, et al. Effects of 1,25(OH)2D3 in immune response regulation of systemic lupus erythematosus (SLE) patient with hypovitamin D. Int J Clin Exp Med. 2014;7(1):22–31.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Toubi E, Shoenfeld Y. The role of vitamin D in regulating immune responses. Isr Med Assoc J. 2010;12(3):174–5.PubMedGoogle Scholar
  32. 32.
    Banica LM, Besliu AN, Pistol GC, Stavaru C, Vlad V, Predeteanu D, et al. Dysregulation of anergy-related factors involved in regulatory T cells defects in systemic lupus erythematosus patients: rapamycin and vitamin D efficacy in restoring regulatory T cells. Int J Rheum Dis. 2014;19:1–10.Google Scholar
  33. 33.
    Handono K, Marisa D, Kalim H. Association between the low levels of vitamin D and Treg function in systemic lupus erythematosus patients. Acta Med Indones. 2013;45(1):26–31.PubMedGoogle Scholar
  34. 34.
    Lertratanakul A, Wu P, Dyer A, Urowitz M, Gladman D, Fortin P, et al. 25-Hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res (Hoboken). 2014;66(8):1167–76.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Yap KS, Northcott M, Hoi AB-Y, Morand E, Nikpour M. Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. Lupus Sci Med. 2015;2(1):e000064.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Mandal M, Tripathy R, Panda AK, Pattanaik SS, Dakua S, Pradhan A, et al. Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. Arthritis Res Ther. 2014;16(1):R49.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Emerah AA, El-Shal AS. Role of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D level in Egyptian female patients with systemic lupus erythematosus. Mol Biol Rep. 2013;40(11):6151–62.PubMedCrossRefGoogle Scholar
  38. 38.
    Sakthiswary R, Raymond AA. The clinical significance of vitamin D in systemic lupus erythematosus: a systematic review. PLoS One. 2013;8(1):1–6.CrossRefGoogle Scholar
  39. 39.
    Tay SH, Ho CS, Ho RC-M, Mak A. 25-Hydroxyvitamin D 3 deficiency independently predicts cognitive impairment in patients with systemic lupus Erythematosus. PLoS One. 2015;10(12):e0144149. Public Library of Science.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Sahebari M, Nabavi N, Salehi M. Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confounders. Lupus. 2014;23(11):1164–77.PubMedCrossRefGoogle Scholar
  41. 41.
    Attar SM, Siddiqui AM. Vitamin D deficiency in patients with systemic lupus erythematosus. Oman Med J. 2013;28(1):42–7.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 2013;65(7):1865–71.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Lima GL, Paupitz J, Aikawa NE, Takayama L, Bonfa E, Pereira RMR. A randomized double-blind placebo-controlled trial of vitamin D supplementation in adolescents and young adults with Juvenile-onset SLE: improvement in disease activity and fatigue scores. Arthritis Care Res (Hoboken). 2016;68(1):91–8.CrossRefGoogle Scholar
  44. 44.
    Andreoli L, Dall’Ara F, Piantoni S, Zanola A, Piva N, Cutolo M, et al. A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus. Lupus. 2015;24(4–5):499–506.PubMedCrossRefGoogle Scholar
  45. 45.
    Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–26.PubMedCrossRefGoogle Scholar
  46. 46.
    Alberti KGMM, Zimmet PZFT. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53. Wiley Online Library.PubMedCrossRefGoogle Scholar
  47. 47.
    Mohr SB, Garland CF, Gorham ED, Garland FC. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia. 2008;51(8):1391–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358(9292):1500–3.PubMedCrossRefGoogle Scholar
  49. 49.
    Dahlquist G. Vitamin D supplement in early childhood and risk for Type I (insulin- dependent) diabetes mellitus. Diabetologia. 1999;42(1):51–4.CrossRefGoogle Scholar
  50. 50.
    Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child. 2008;93(6):512–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Sørensen IM, Joner G, Jenum PA, Eskild A, Torjesen PA, Stene LC. Maternal serum levels of 25-hydroxy-vitamin D during pregnancy and risk of type 1 diabetes in the offspring. Diabetes. 2012;61(1):175–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Mohammadian S, Fatahi N, Zaeri H, Vakili MA. Effect of vitamin d3 supplement in glycemic control of pediatrics with type 1 diabetes mellitus and vitamin d deficiency. J Clin Diagn Res. 2015;9(3):SC05–7.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Engelen L, Schalkwijk CG, Eussen SJPM, Scheijen JLJM, Soedamah-Muthu SS, Chaturvedi N, et al. Low 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 levels are independently associated with macroalbuminuria, but not with retinopathy and macrovascular disease in type 1 diabetes: the EURODIAB prospective complications study. Cardiovasc Diabetol. 2015;14(1):1–9.CrossRefGoogle Scholar
  54. 54.
    Zeitz U. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003;17:509–11.PubMedCrossRefGoogle Scholar
  55. 55.
    Rice CM, Cottrell D, Wilkins A, Scolding NJ. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry. 2013;84(10):1100–6. BMJ Publishing Group Ltd.PubMedCrossRefGoogle Scholar
  56. 56.
    Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.PubMedCrossRefGoogle Scholar
  57. 57.
    Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7(3):268–77.PubMedCrossRefGoogle Scholar
  58. 58.
    Watad A, Azrielant S, Soriano A, Bracco D, Abu Much A, Amital H. Association between seasonal factors and multiple sclerosis. Eur J Epidemiol. 2016;25:1–9. Springer.Google Scholar
  59. 59.
    Munger KL, Zhang SM, O’Reilly E, Hernán MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Nepom GT, Erlich H. MHC class-II molecules and autoimmunity. Annu Rev Immunol. 1991;9(1):493–525. Annual Reviews 4139 El Camino Way, PO Box 10139, Palo Alto, CA 94303-0139, USA.PubMedCrossRefGoogle Scholar
  61. 61.
    Silva AM, Pereira C, Bettencourt A, Carvalho C, Couto AR, Leite MI, et al. The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population. J Neurol Sci. 2007;258(1):69–74. Elsevier.PubMedCrossRefGoogle Scholar
  62. 62.
    Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009;5(2):1–6.CrossRefGoogle Scholar
  63. 63.
    Auer DP, Schumann EM, Kümpfel T, Gössl C, Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol. 2000;47(2):276–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306–14.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72(2):234–40.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol. 2003;134(0165–5728 (Print)):128–32.PubMedCrossRefGoogle Scholar
  67. 67.
    Podolsky DK. Inflammatory bowel disease. N Engl J Med. 1991;325(13):928–37. Mass Medical Soc.PubMedCrossRefGoogle Scholar
  68. 68.
    Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12(5):S3–9. Wiley Online Library.PubMedCrossRefGoogle Scholar
  69. 69.
    Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, Zadvornova Y, Binion DG, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35(3):308–16.PubMedCrossRefGoogle Scholar
  70. 70.
    Cantorna MT, McDaniel K, Bora S, Chen J, James J. Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. Exp Biol Med. 2014;239(11):1524–30. SAGE Publications.CrossRefGoogle Scholar
  71. 71.
    Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130(11):2648–52.PubMedCrossRefGoogle Scholar
  72. 72.
    Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol. 2003;17(12):2386–92.PubMedCrossRefGoogle Scholar
  73. 73.
    Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124(3):795–841.PubMedCrossRefGoogle Scholar
  74. 74.
    Kerr GS, Sabahi I, Richards JS, Caplan L, Cannon GW, Reimold A, et al. Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol. 2011;38(1):53–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME, et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol. 2006;24(6):702–4.PubMedGoogle Scholar
  76. 76.
    Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum. 2004;50(1):72–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis. 2008;67(4):530–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Orgaz-Molina J, Buendía-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J Am Acad Dermatol. 2012;67(5):931–8. Elsevier.PubMedCrossRefGoogle Scholar
  79. 79.
    Park B-S, Lee D-Y, Youn J-I, Park J-S, Kim I-G. Vitamin D receptor polymorphism is associated with psoriasis. J Invest Dermatol. 1999;112(1):113–6. Elsevier.PubMedCrossRefGoogle Scholar
  80. 80.
    Smith EL, Walworth NC, Holick MF. Effect of 1α, 25-dihydroxyvitamin D 3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol. 1986;86(6):709–14. Elsevier.PubMedCrossRefGoogle Scholar
  81. 81.
    Holick MF. Clinical efficacy of 1,25-dihydroxyvitamin D3 and its analogues in the treatment of psoriasis. Retinoids. 1998;14(1):12–7.Google Scholar
  82. 82.
    Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332(9):581–9. Mass Medical Soc.PubMedCrossRefGoogle Scholar
  83. 83.
    Bizzaro G, Shoenfeld Y. Vitamin D and thyroid autoimmune diseases: the known and the obscure. Immunol Res. 2015;61(1–2):107–9. Springer Science & Business Media.PubMedCrossRefGoogle Scholar
  84. 84.
    Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Dankó K, et al. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol. 2011;8(3):243–7. Nature Publishing Group.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Do JE, Kwon SY, Park S, Lee E-S. Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet’s disease. Rheumatology. 2008;47(6):840–8. Br Soc Rheumatology.PubMedCrossRefGoogle Scholar
  86. 86.
    Vacca A, Cormier C, Piras M, Mathieu A, Kahan A, Allanore Y. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol. 2009;36(9):1924–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Corrado A, Colia R, Mele A, Di Bello V, Trotta A, Neve A, et al. Relationship between body mass composition, bone mineral density, skin fibrosis and 25 (OH) vitamin D serum levels in systemic sclerosis. PLoS One. 2015;10(9):e0137912. Public Library of Science.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today. 1995;16(1):34–8. Elsevier.PubMedCrossRefGoogle Scholar
  89. 89.
    Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol. 2000;85(1):9–21. Elsevier.PubMedCrossRefGoogle Scholar
  90. 90.
    Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517.PubMedCrossRefGoogle Scholar
  91. 91.
    Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HFJ, O’Garra A. 1α, 25-Dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells. J Immunol. 2001;167(9):4974–80. Am Assoc Immnol.CrossRefPubMedGoogle Scholar
  92. 92.
    Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183(9):5458–67. Am Assoc Immnol.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Cantorna MT, Woodward WD, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-β1 and IL-4. J Immunol. 1998;160(11):5314–9. Am Assoc Immnol.PubMedGoogle Scholar
  94. 94.
    Staeva-Vieira TP, Freedman LP. 1,25-dihydroxyvitamin D3 inhibits IFN-γ and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol. 2002;168(3):1181–9. Am Assoc Immnol.PubMedCrossRefGoogle Scholar
  95. 95.
    Joshi S, Pantalena L-C, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, et al. 1,25-Dihydroxyvitamin D3 ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol. 2011;31(17):3653–69. Am Soc Microbiol.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+ CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol. 1998;160(3):1212–8. Am Assoc Immnol.PubMedGoogle Scholar
  97. 97.
    Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1α, 25-dihydroxyvitamin D3 analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes. 2002;51(5):1367–74. Am Diabetes Assoc.PubMedCrossRefGoogle Scholar
  98. 98.
    Prietl B, Pilz S, Wolf M, Tomaschitz A, Obermayer-Pietsch B, Graninger W, et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr Med Assoc J. 2010;12(3):136–9.PubMedGoogle Scholar
  99. 99.
    Linker-Israeli M, Elstner E, Klinenberg JR, Wallace DJ, Koeffler HP. Vitamin D 3 and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol. 2001;99(1):82–93. Elsevier.PubMedCrossRefGoogle Scholar
  100. 100.
    Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294:1540–3.PubMedCrossRefGoogle Scholar
  101. 101.
    Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18(Figure 1):767–811.PubMedCrossRefGoogle Scholar
  102. 102.
    Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun. 2000;270(3):701–8. Elsevier.PubMedCrossRefGoogle Scholar
  103. 103.
    Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem. 2003;88(2):227–33. Wiley Online Library.PubMedCrossRefGoogle Scholar
  104. 104.
    Penna G, Adorini L. 1α, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164(5):2405–11. Am Assoc Immnol.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Sheba Medical Center, The Zabludowicz Center for Autoimmune DiseasesRamat-GanIsrael
  2. 2.Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael
  3. 3.Incumbent of the Laura Schwarz-Kip Chair for Research of Autoimmune DiseasesTel-Aviv UniversityTel-AvivIsrael

Personalised recommendations